Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2012-2015) [0.03%]
关于表皮肽受体调节剂的专利回顾及其在炎症疾病中的潜在应用（2012-2015）
Yung-Fong Tsai,Shun-Chin Yang,Tsong-Long Hwang
Yung-Fong Tsai
The activation of leukocytes and the subsequent immune cascade play an essential role in sterile and infectious inflammation. Dysregulation of these immune responses or excess leukocyte activation can induce tissue damage, organ dysfunction...
Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016) [0.03%]
库欣综合症的治疗化合物专利综述(2012-2016)
Li Ma,Lina Yin,Qingzhong Hu
Li Ma
Endogenous Cushing's syndrome (CS) is a set of disorders caused by chronic exposure to excess glucocorticoids induced by neuroendocrine tumors in pituitary, adrenals, and infrequently other sites (ectopic ACTH syndrome). Due to various como...
Chang Li,Xiaofei Xu,Zhihao Tao et al.
Chang Li et al.
Resveratrol is a well-studied natural small molecule that possesses diverse bioactivities. Chemical derivation based on the resveratrol scaffold is of great importance to overcome the drawbacks of resveratrol and to improve its therapeutic ...
Saúl Abenhamar Navarro,Esmeralda Carrillo,Carmen Griñán-Lisón et al.
Saúl Abenhamar Navarro et al.
Introduction: Cancer is considered the second leading cause of death worldwide despite the progress made in early detection and advances in classical therapies. Advancing in the fight against cancer requires the developme...
Urate transporter URAT1 inhibitors: a patent review (2012 - 2015) [0.03%]
尿酸转运蛋白URAT1抑制剂专利回顾(2012-2015)
Ying Pan,Ling-Dong Kong
Ying Pan
Human urate transporter 1 (URAT1, encoded by SLC22A12) has been identified as a key urate transporter expressed at the apical membrane of renal proximal tubule cells for regulating urate homeostasis. Therefore, URAT1 is an attractive target...
Bone and metal targeted polymeric nanoparticles (US20150125391 A1): a patent evaluation [0.03%]
一种骨和金属靶向聚合物纳米粒子专利分析（US20150125391 A1）
Lin Li,Quan Huang,Changping Wang et al.
Lin Li et al.
Introduction: Delivery of therapeutic agents to bone is crucial for the treatment of bone metastasis and other bone diseases. The present invention patent relates to bone- and metal-targeted polymeric nanoparticles for ta...
Katarzyna A Ludwik,Deborah A Lannigan
Katarzyna A Ludwik
Introduction: The p90 ribosomal S6 kinases (RSK) are a family of Ser/Thr protein kinases that are downstream effectors of MEK1/2-ERK1/2. Increased RSK activation is implicated in the etiology of multiple pathologies, incl...
Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015) [0.03%]
酰基载体蛋白烯脂酰还原酶抑制剂的专利回顾(2011-2015)
Jan Zitko,Martin Doležal
Jan Zitko
Introduction: Enoyl-(acyl-carrier-protein) reductase (ENR) is a limiting step enzyme in the Fatty Acid Synthase II system. In mammals, there is no homologue to ENR, which makes it an optimal candidate target for selective...
Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182 [0.03%]
基于吡唑并[1,5-a]嘧啶的巨环类抗HIV-1感染的新药：对专利WO2015123182的评估
Lin Sun,Ping Gao,Peng Zhan et al.
Lin Sun et al.
The emergence of drug resistance in Combination Antiretroviral Therapy (cART) confirms a continuing need to investigate novel HIV-1 inhibitors with unexplored mechanisms of action. Recently, a series of pyrazolopyrimidine-based macrocyclic ...
Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016) [0.03%]
碳酸酐酶抑制剂专利文献(2011-2016)进展综述
Carrie Lomelino,Robert McKenna
Carrie Lomelino
Introduction: A large area of carbonic anhydrase (CA) research focuses on the inhibition of human CA IX and CA XII, as these isoforms have been designated as biomarkers and therapeutic targets for various cancer types. ...